Trying to select among three antihypertensive drugs: ramipril, telmisartan and valsartan in the treatment of hypertension according to the blood pressure and cardiovascular risk Review article
Article Sidebar
Published:
Dec 31, 2012
Keywords:
antihypertensive drugs, therapy choice
Main Article Content
Abstract
Choice of antihypertensive therapy aimed at reducing high blood pressure to reach target levels is based on multivariate criteria including drug pharmacology and patients’ clinical characteristic. The article attempts to define the target patient groups for the selected three antihypertensive drugs: ramipril, telmisartan and valsartan.
Article Details
How to Cite
Grabowski , M. (2012). Trying to select among three antihypertensive drugs: ramipril, telmisartan and valsartan in the treatment of hypertension according to the blood pressure and cardiovascular risk. Medycyna Faktow (J EBM), 5(4(17), 39-46. Retrieved from https://journalsmededu.pl/index.php/jebm/article/view/2440
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Widecka K., Grodzicki T., Narkiewicz K. et al.: Zasady postępowania w nadciśnieniu tętniczym – 2011 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze 2011; 15(2): 55-82.
2. Filipiak K.J., Gaciong Z., Narkiewicz K., Tykarski A.: Konsensus w sprawie pozycji antagonistów receptora AT1 angiotensyny i inhibitorów konwertazy angiotensyny w leczeniu nadciśnienia tętniczego i jego powikłań sercowo-naczyniowych. Nadciśnienie Tętnicze 2009; 13(1).
3. Opolski G., Filipiak K.J. (red.). Leki hamujące układ renina-angiotensyna-aldosteron. Wydawnictwo Medyczne Urban & Partner, Wrocław 2000.
4. Kjoller-Hansen L., Steffensen R., Grande P.: The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J. Am. Coll. Cardiol. 2000 Mar 15; 35(4): 881-888.
5. Yusuf S., Sleight P., Pogue J. et al.: Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342: 145-53.
6. Williams B., Gosse P., Lowe L., Harper R.; PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J. Hypertens. 2006 Jan; 24(1): 193-200.
7. Williams B., Lacourcière Y., Schumacher H., Gosse P., Neutel J.M.: Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J. Hum. Hypertens. 2009; 23(9): 610-9.
8. The ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-59.
9. Malacco E., Santonastaso M., Varì N.A. et al.: Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin. Ther. 2004; 26(6): 855-65.
10. Julius S., Kjeldsen S.E., Weber M. et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-31.
11. Julius S., Weber M.A., Kjeldsen S.E. et al.: The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48(3): 385-91.
12. Schmieder R.E., Kjeldsen S.E., Julius S. et al.: Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J. Hypertens. 2008; 26(3): 403-11.
2. Filipiak K.J., Gaciong Z., Narkiewicz K., Tykarski A.: Konsensus w sprawie pozycji antagonistów receptora AT1 angiotensyny i inhibitorów konwertazy angiotensyny w leczeniu nadciśnienia tętniczego i jego powikłań sercowo-naczyniowych. Nadciśnienie Tętnicze 2009; 13(1).
3. Opolski G., Filipiak K.J. (red.). Leki hamujące układ renina-angiotensyna-aldosteron. Wydawnictwo Medyczne Urban & Partner, Wrocław 2000.
4. Kjoller-Hansen L., Steffensen R., Grande P.: The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES). J. Am. Coll. Cardiol. 2000 Mar 15; 35(4): 881-888.
5. Yusuf S., Sleight P., Pogue J. et al.: Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med. 2000; 342: 145-53.
6. Williams B., Gosse P., Lowe L., Harper R.; PRISMA I Study Group. The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I). J. Hypertens. 2006 Jan; 24(1): 193-200.
7. Williams B., Lacourcière Y., Schumacher H., Gosse P., Neutel J.M.: Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials. J. Hum. Hypertens. 2009; 23(9): 610-9.
8. The ONTARGET Investigators, Yusuf S., Teo K.K., Pogue J. et al.: Telmisartan, ramipril, or both in patients at high risk for vascular events. N. Engl. J. Med. 2008; 358: 1547-59.
9. Malacco E., Santonastaso M., Varì N.A. et al.: Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study. Clin. Ther. 2004; 26(6): 855-65.
10. Julius S., Kjeldsen S.E., Weber M. et al.: Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-31.
11. Julius S., Weber M.A., Kjeldsen S.E. et al.: The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy. Hypertension 2006; 48(3): 385-91.
12. Schmieder R.E., Kjeldsen S.E., Julius S. et al.: Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J. Hypertens. 2008; 26(3): 403-11.